Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy

作者：Bee Luan Khoo, Soo Chin Lee, Prashant Kumar, Tuan Zea Tan, Majid Ebrahimi Warkiani, Samuel G.W. Ow, Sayantani Nandi, Chwee Teck Lim, Jean Paul Thiery · 发表于：Oncotarget · 年份：2015 · DOI：10.18632/oncotarget.3903 · 被引用次数：151 · 研究领域：Cancer Cells and Metastasis、Cancer, Stress, Anesthesia, and Immune Response、FOXO transcription factor regulation

// Bee Luan Khoo 1, * , Soo Chin Lee 2, 3, * , Prashant Kumar 4,* , Tuan Zea Tan 3 , Majid Ebrahimi Warkiani 5, 6 , Samuel GW. Ow 2 , Sayantani Nandi 4 , Chwee Teck Lim 4, 5, 7, 8, * , Jean Paul Thiery 3, 4, 9, * 1 Mechanobiology Institute, National University of Singapore, Singapore 2 Department of Hematology-Oncology, National University Cancer Institute, National University Hospital, Singapore 3 Cancer Science Institute of Singapore, National University of Singapore, Singapore 4 Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), Singapore 5 BioSystems and Micromechanics (BioSyM) IRG, Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore 6 School of Mechanical and Manufacturing Engineering, University of New South Wales, Sydney, Australia 7 Department of Biomedical Engineering, National University of Singapore, Singapore 8 Department of Mechanical Engineering, National University of Singapore, Singapore 9 Department of Biochemistry Yong Loo Lin School of Medicine, National University of Singapore, Singapore * These authors have contributed equally to this work Correspondence to: Jean Paul Thiery, e-mail: bchtjp@nus.edu.sg Keywords: breast cancer, circulating tumor cells, CTCs, enrichment Received: February 16, 2015 Accepted: April 24, 2015 Published: May 06, 2015 ABSTRACT Circulating tumor cells (CTCs) are considered as surrogate markers for prognosticating and evaluating patient treatment responses. Here, 2...